100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
CAMBRIDGE, Mass., Feb. 08, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT) today announced the closing of its initial public offering of 6,785,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, including 885,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option. All of the shares in the offering were sold by Editas Medicine. The shares began trading on the NASDAQ Global Select Market on February 3, 2016.
Morgan Stanley and J.P. Morgan acted as joint book-running managers for the offering. Cowen and Company acted as lead manager, and JMP Securities acted as co-manager for the offering.
A registration statement relating to the securities being sold in this offering was filed with and declared effective by the Securities and Exchange Commission. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]
